Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 22

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 22
---
 common stock and for each Pre-Funded Warrant sold in this offering, the number of Series B Warrants sold in this offering will not change as a result of a change in the mix of the shares of our common stock and Pre-Funded Warrants sold.Following the receipt of Stockholder Approval, holders the Series B Warrants may effect an “alternative cashless exercise” at any time while the Series B Warrants are outstanding without making any cash payments. Under the alternative cashless exercise option, a holder of a Series B Warrant has the right to receive an aggregate number of shares of Series B Preferred Stock equal to the product of (i) the aggregate number of shares of Series B Preferred Stock that would be issuable upon a cash rather than a cashless exercise of the Series B Warrant and (ii) 3.0. Accordingly, it is highly unlikely that a holder of the Series B Warrants would wish to pay an exercise price in cash to receive .001 share of Series B Preferred Stock when they could instead choose the alternative cashless exercise option and pay no cash to receive .003 shares of Series B Preferred Stock. As a result, we will likely not receive any additional funds and do not expect to receive any additional funds upon the exercise of the Series B Warrants.​​​​Series B Preferred Stock​This prospectus also relates to the offering of the shares of Series B Preferred Stock issuable upon the exercise of the Series Warrants. The Series B Preferred Stock is not convertible until the Initial Conversion Date, starting at which time each  share of the Series B Preferred Stock is convertible into 1,000 shares of common stock. Notwithstanding the foregoing, we shall not effect any conversion of the Series B Preferred Stock, to the extent that, after giving effect to an attempted conversion, the holder of shares of Series B Preferred Stock (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% of the shares of common stock then outstanding after giving effect to such exercise. In the event our stockholders do not approve the Charter Amendment, the Series B Preferred Stock will not be convertible into common stock and the value of the Series Warrants and the Series B Preferred Stock may be negatively affected. For additional information, see the subsection entitled “Description of Securities We Are Offering —Series B Convertible Preferred Stock” in this prospectus.​​​